INS and type 2 diabetes mellitus: This hypothesis is supported by evidence from an outcome trial comparing different treatment regimens for type 2 diabetes, including glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose co-transporter 2 inhibitors (SGLT-2i), and insulin monotherapy.